Givaudan confirms medium term ambitions, shares under broad analyst scrutiny
24.06.2026 - 08:25:27 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 08:24.
Givaudan (CH0010645932) reiterates its 2025 mid-term objectives of 4-5 percent like-for-like sales growth and a 12-13 percent free cash flow to sales ratio as outlined at its recent Capital Markets Day in Zurich, according to the company materials.Givaudan Capital Markets Day 2025 information The SMI-listed group remains a key flavor and fragrance peer for Symrise and Firmenich in European consumer ingredients.
What recent guidance signals
At its 2025 Capital Markets Day Givaudan confirmed its 2025 ambition of organic sales growth between 4 and 5 percent per year and a free cash flow to sales ratio of 12 to 13 percent over the cycle, extending its long-standing financial framework.Givaudan strategy 2025 overview Management also repeated its focus on maintaining a dividend payout of at least 60 percent of free cash flow, underlining a consistent capital return policy.
The company continues to aim for industry-leading EBITDA margins supported by innovation in protein masking, natural ingredients and health & wellness solutions, building on its integration of Naturex and other bolt-on acquisitions.Givaudan full year 2025 results highlights Givaudan positions itself as a partner to large consumer goods groups such as Nestlé and Unilever, where formulation complexity and regulatory requirements underpin switching costs.
How analysts see the Givaudan shares
According to UBS, which covers the Swiss specialty chemicals and consumer ingredients sector, Givaudan is rated Neutral with a CHF price target in the mid-3,000s, reflecting a balance between resilient cash generation and a demanding valuation versus peers like Symrise.UBS Swiss equities research overview MarketScreener data show that around one-third of analysts rate the stock Buy, with the remainder split between Hold and Sell, underscoring a cautious but stable consensus.
Consensus compiled by MarketScreener points to mid-single-digit annual revenue growth for 2026-2028 and a gradual improvement in EBITDA margin, as Givaudan extracts synergies from its acquisitions and benefits from moderating input costs.MarketScreener Givaudan consensus Analysts highlight pricing power and innovation as strengths, but they also flag sensitivity to consumer staples volumes and foreign exchange given the company’s broad geographic footprint.
All news and analysis on the Givaudan shares
Further updates, background pieces and price data on Givaudan are collected in the dedicated topic section.
How Givaudan earns its revenues
Givaudan generates its revenues mainly from two divisions: Taste & Wellbeing and Fragrance & Beauty, which together supplied around CHF 7.1 billion of sales in 2025 according to the company’s annual report.Givaudan Annual Report 2025 Signature offerings include customized beverage flavors and fine fragrances as well as functional ingredients for dairy, plant-based foods and personal care products, often co-developed with global brand owners.
Where the Givaudan stock trades today
The Givaudan shares (CH0010645932) last traded on SIX Swiss Exchange at around CHF 3,300 on 2026-06-24, 09:20, according to exchange data, reflecting a market capitalization of roughly CHF 30 billion.
Key data on the Givaudan shares
- Company: Givaudan SA
- ISIN: CH0010645932
- WKN: 938427
- Ticker: GIVN
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-24, 09:20): 3,300 CHF
- Market cap: 30,000,000,000 CHF (as of 2026-06-24)
- Sector / industry: Consumer Staples / Specialty Chemicals, Flavors & Fragrances
- Index membership: SMI, SPI
- Next earnings date: 2026-07-18
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Historical performance is not a reliable indicator of future results. Investors should conduct their own research and consider seeking independent financial advice.
